Loading...
•
Mar 31, 2024
Stryker Q1 2024 Earnings Report
Stryker reported a strong first quarter with significant growth in net sales and earnings.
Key Takeaways
Stryker's Q1 2024 results showed a 9.7% increase in reported net sales to $5.2 billion and a 10.0% increase in organic net sales. The company's reported EPS increased by 33.1% to $2.05, and adjusted EPS increased by 16.8% to $2.50. Management is confident in the company's ability to grow sales and drive strong adjusted earnings growth in 2024.
Reported net sales increased by 9.7% to $5.2 billion.
Organic net sales increased by 10.0%.
Reported EPS increased by 33.1% to $2.05.
Adjusted EPS increased by 16.8% to $2.50.
Stryker
Stryker
Stryker Revenue by Segment
Revenue by Segment
MedSurg and Neurotechnology Revenue
CapyFin.comOrthopaedics Revenue
CapyFin.com Forward Guidance
Stryker now expects full year 2024 organic net sales growth to be in the range of 8.5% to 9.5% and adjusted net earnings per diluted share to be in the range of $11.85 to $12.05.
Positive Outlook
- Strong procedural volumes
- Healthy demand for capital products
- Commitment to expanding operating margins
Challenges Ahead
- Foreign exchange rates will moderately unfavorably impact net sales for the full year.
- Adjusted net earnings per diluted share will be negatively impacted at the higher end of our previously guided range of $0.05 to $0.10 for the full year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income